Pulmonary Arterial Hypertension (PAH) is a fatal disease characterized by impaired regulation of pulmonary hemodynamics and vascular growth. The excessive growth and dysfunction of endothelial cells that line the blood vessels in PAH is the continuing focus of our research. In the current award period, we established primary cell culture methods from PAH lungs;mechanistically linked low levels of nitric oxide (NO) to PAH in humans;identified pathologic expression of HIF-1a and its role in the metabolic shift to aerobic glycolysis in PAH;and defined a novel myelopulmonary disease paradigm in PAH pathogenesis. In this extension, the hypotheses and aims remain well within the scope of the award.
In Aim 1, we define mechanisms of low NO production by PAH pulmonary artery endothelial cells (PAEC). We hypothesize that low NO production is due to reduced activity of the endothelial NO synthase (eNOS) and plan to uncover mechanisms. We will measure intracellular NO production in PAEC in real time and define functional endophenotypes. Because eNOS activity depends on tetrahydrobiopterin (H4B), we will quantify H4B in PAEC and serum of patients in comparison to controls. Likewise, we investigate intracellular mechanisms that regulate eNOS phosphorylation states, i.e. kinase and phosphatase pathways.
In Aim 2, we identify HIF-1 a expression in PAH and the mechanisms accounting for expression. We hypothesize that HIF-1a expression is fundamental in the pathologic angiogenesis and preferential energy generation by glycolysis in PAH. We determine mitochondrial and glycolytic bioenergetics in PAH PAEC and pulmonary artery smooth muscle cells. We extend mechanistic studies to iron metabolism, which is important to understanding HIF-1a and bioenergetics. We measure hepcidin in PAH patients in comparison to healthy people to test the hypothesis that higher hepcidin accounts for lower iron in PAH.
In Aim 3, we determine consequences and relevance of HIF-expression and myeloproliferative processes to pathophysiology of PAH. We hypothesize that HIF- expression is mechanistically important to PAH pathogenesis by establishing a pathologic myeloproliferative process that consequently promotes and sustains the proliferative panvasculopathy of PAH. We test .the effects of transplantation of hematopoietic and mesenchymal stem cells isolated from PAH'bone marrow into NOD-SCID mice. Similarty, we plan mechanistic transplantation experiments using marrows from Caveolin-1 deficient mice, which develop pulmonary hypertension when exposed to hypoxia. We will quantitate lung vasculature, activation and injury of vascular endothelium, and cardiac function in the Wild type mice that receive Caveolin-1 deficient stem cells. Overall, in this extension ofthe MERIT, our long-term goal remains the same: to define the pathophysiology of abnormal pulmonary vascular growth and endothelial dysfunction, and in so doing, apply the knowledge to improve the care of patients with PAH.

Public Health Relevance

Overall our goals are to define the pathophysiology of the abnormal vascular growth in Pulmonary Arterial Hypertension (PAH), and in so doing, apply the knowledge to improve the care of patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
4R37HL060917-16
Application #
8668566
Study Section
No Study Section (in-house review) (NSS)
Program Officer
Xiao, Lei
Project Start
1999-04-01
Project End
2019-06-30
Budget Start
2014-08-01
Budget End
2015-06-30
Support Year
16
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Asosingh, Kewal; Wanner, Nicholas; Weiss, Kelly et al. (2017) Bone marrow transplantation prevents right ventricle disease in the caveolin-1-deficient mouse model of pulmonary hypertension. Blood Adv 1:526-534
Cheong, Hoi I; Janocha, Allison J; Monocello, Lawrence T et al. (2017) Alternative hematological and vascular adaptive responses to high-altitude hypoxia in East African highlanders. Am J Physiol Lung Cell Mol Physiol 312:L172-L177
Hwangbo, Cheol; Lee, Heon-Woo; Kang, Hyeseon et al. (2017) Modulation of Endothelial Bone Morphogenetic Protein Receptor Type 2 Activity by Vascular Endothelial Growth Factor Receptor 3 in Pulmonary Arterial Hypertension. Circulation 135:2288-2298
Chen, Jiwang; Sysol, Justin R; Singla, Sunit et al. (2017) Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension. Circulation 135:1532-1546
Cheong, Hoi I; Asosingh, Kewal; Stephens, Olivia R et al. (2016) Hypoxia sensing through ?-adrenergic receptors. JCI Insight 1:e90240
Asosingh, Kewal; Farha, Samar; Erzurum, Serpil C (2016) Myeloid Targets for Pulmonary Arterial Hypertension: Time for Another Look. Am J Respir Crit Care Med 194:384
Ghosh, Sudakshina; Gupta, Manveen; Xu, Weiling et al. (2016) Phosphorylation inactivation of endothelial nitric oxide synthesis in pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 310:L1199-205
Yuan, Yiyuan; Hakimi, Parvin; Kao, Clara et al. (2016) Reciprocal Changes in Phosphoenolpyruvate Carboxykinase and Pyruvate Kinase with Age Are a Determinant of Aging in Caenorhabditis elegans. J Biol Chem 291:1307-19
Liu, Fei; Haeger, Christina Mallarino; Dieffenbach, Paul B et al. (2016) Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertension. JCI Insight 1:
Farha, Samar; Hu, Bo; Comhair, Suzy et al. (2016) Mitochondrial Haplogroups and Risk of Pulmonary Arterial Hypertension. PLoS One 11:e0156042

Showing the most recent 10 out of 62 publications